Predictions
Acadia Pharmaceuticals
Start price
Target price
Perf. (%)
€21.86
12.04.22
12.04.22
-
12.04.23
12.04.23
-23.60%
12.04.23
12.04.23
Novocure Ltd
Start price
Target price
Perf. (%)
€64.20
16.03.22
16.03.22
€68.00
16.03.23
16.03.23
-6.99%
17.03.23
17.03.23
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Nektar Therapeutics
Start price
Target price
Perf. (%)
€2.02
23.01.23
23.01.23
-
23.01.24
23.01.24
-28.00%
03.03.23
03.03.23
Risky Investment
Novocure Ltd
Start price
Target price
Perf. (%)
€68.89
02.01.23
02.01.23
€30.00
31.12.25
31.12.25
71.43%
05.01.23
05.01.23
Could be very worthwhile Investment >20% year
Tandem Diabetes Care Inc
Start price
Target price
Perf. (%)
€136.00
28.12.21
28.12.21
€142.00
28.12.22
28.12.22
-70.42%
29.12.22
29.12.22
Could be worthwhile Investment >10% per year
Capable Management
Future proof or reliable business model
Opko Health Inc.
Start price
Target price
Perf. (%)
€4.65
28.12.21
28.12.21
-
28.12.22
28.12.22
-75.54%
29.12.22
29.12.22
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Innovative
Future proof or reliable business model
Sage Therapeutics Inc.
Start price
Target price
Perf. (%)
€37.99
27.12.21
27.12.21
€42.00
27.12.22
27.12.22
-5.05%
28.12.22
28.12.22
Could be worthwhile Investment >10% per year
Neogen Corp.
Start price
Target price
Perf. (%)
€35.40
14.12.21
14.12.21
€38.00
14.12.22
14.12.22
-59.89%
15.12.22
15.12.22
Could be worthwhile Investment >10% per year
Mirati Therapeutics Inc.
Start price
Target price
Perf. (%)
€47.20
07.12.22
07.12.22
-
07.12.23
07.12.23
-16.53%
10.12.22
10.12.22
Risky Investment
Mirati Therapeutics Inc.
Start price
Target price
Perf. (%)
€76.50
21.08.22
21.08.22
€230.00
21.08.23
21.08.23
6.54%
04.09.22
04.09.22
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Probably not worthwhile Investment
Lower EBIT Margin than peer group
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€214.90
21.08.22
21.08.22
€87.00
21.08.23
21.08.23
-3.44%
04.09.22
04.09.22
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Tandem Diabetes Care Inc
Start price
Target price
Perf. (%)
€91.50
10.08.21
10.08.21
-
10.08.22
10.08.22
-42.25%
10.08.22
10.08.22
Global Blood Therapeutics Inc
Start price
Target price
Perf. (%)
€33.09
30.10.21
30.10.21
€45.00
31.12.23
31.12.23
94.65%
05.08.22
05.08.22
Could be very worthwhile Investment >20% year
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€152.65
16.11.21
16.11.21
€200.00
31.01.25
31.01.25
36.59%
03.08.22
03.08.22
Could be worthwhile Investment >10% per year
Halozyme Therapeutics Inc.
Start price
Target price
Perf. (%)
€38.17
08.07.21
08.07.21
-
08.07.22
08.07.22
30.25%
08.07.22
08.07.22
Bluebird Bio Inc.
Start price
Target price
Perf. (%)
€9.23
09.11.21
09.11.21
€7.00
31.12.23
31.12.23
-56.18%
28.06.22
28.06.22
Could be very worthwhile Investment >20% year
Bluebird Bio Inc.
Start price
Target price
Perf. (%)
€2.81
30.05.22
30.05.22
-
30.05.23
30.05.23
23.85%
08.06.22
08.06.22
Risky Investment
Arrowhead Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€54.60
08.07.21
08.07.21
-
08.07.22
08.07.22
-37.34%
21.05.22
21.05.22
Ensign Group Inc.
Start price
Target price
Perf. (%)
€71.50
03.05.21
03.05.21
€78.00
03.05.22
03.05.22
2.80%
04.05.22
04.05.22
Could be worthwhile Investment >10% per year